Trial to reduce HIV reservoirs aiming for treatment-free remission
Treatments studied
Part of Immune system & allergy, Infections clinical trials.
This study tests whether a combination approach, including a drug called nicotinamide (a form of vitamin B3) and other strategies, can reduce the hidden HIV reservoir enough to allow a temporary pause in antiretroviral therapy without the virus rebounding. It is for people who have well-controlled HIV and strong immune systems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Aged 18 to 64 with documented HIV-1 infection.
- On the same HIV medications for at least 2 years, with no changes in the past 6 months.
- Undetectable HIV viral load (below 50 copies/mL) for the past 2 years without any blips.
- Lowest ever CD4 count above 350 and current CD4 count above 500.
- HIV virus type is R5 (as determined by a blood test).
- No active serious infections or other conditions that could interfere with the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether some people with HIV can keep the virus controlled even if they temporarily stop HIV medicines (an “analytic treatment interruption”). If you qualify, it may help researchers learn what it would take for an HIV cure.
This study compares how active the immune system is and how large the “hidden” HIV reservoir is in people on two different HIV treatment types. It may help researchers understand whether staying on a tenofovir-containing regimen leads to better control of HIV hiding in the body.
This trial tests whether you can safely stop your HIV medication for a while if your immune system has specific markers that might help control the virus. The goal is to see if a treatment pause could be an option for people like you.
This trial tests whether a combination of powerful antibodies (bNAbs) can help control HIV after stopping standard HIV treatment. Participants will pause their daily HIV medications while receiving these antibodies, and doctors will closely monitor their immune system and virus levels. It's for people who are already well-controlled on HIV treatment and have participated in a specific earlier study.
This study tests whether combining two or more investigational drugs that can activate the hidden HIV reservoir in your body might help eliminate it. The goal is to see if this approach is safe and could help lead to a cure for HIV.
This trial tests whether the drug dasatinib can reduce the hidden HIV reservoir in people who have had their virus well-controlled on HIV medications for a long time. It may help move toward a cure by targeting the cells where HIV hides.
Hear when a new HIV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.